Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity

Trial Profile

Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 May 2019

At a glance

  • Drugs Lisdexamfetamine (Primary)
  • Indications Anxiety disorders; Attention-deficit hyperactivity disorder; Major depressive disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 01 Feb 2017 Planned End Date changed from 1 Jan 2017 to 1 Mar 2017.
    • 01 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top